Abstract
HuiYan Zhao, Ojin Kwon, Jae Young Jang, Gyu Ri Jeon, Ye-chae Hwang, Eunbyul Cho, 차지윤, Eun Kyoung Ahn, Seong-Uk Park, Jung-Hee Jang
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Proteomic analysis of dopamine and α‐synuclein interplay in a cellular model of Parkinson’s disease pathogenesis.
10.1111/j.1742-4658.2010.07896.x · 2010
Parkinson disease.
10.1038/nrdp.2017.13 · 2017
Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study.
10.1016/s1474-4422(14)70287-x · 2015
Discovery of Parkinson’s disease states and disease progression modelling: a longitudinal data study using machine learning.
10.1016/s2589-7500(21)00101-1 · 2021
Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression.
10.1093/brain/awx118 · 2017
Prognosis and neuropathologic correlation of clinical subtypes of Parkinson disease.
10.1001/jamaneurol.2018.4377 · 2019
Disease progression of data-driven subtypes of Parkinson’s Disease: 5-Year longitudinal study from the early Parkinson’s Disease Longitudinal Singapore (PALS) Cohort.
10.3233/jpd-230209 · 2024
Two distinct trajectories of clinical and neurodegeneration events in Parkinson’s disease.
10.1038/s41531-023-00556-3 · 2023
Do Parkinson’s Disease clinical subtypes really exist?
10.5603/pjnns.103572 · 2025
Herbal medicines for Parkinson’s disease: a systematic review of randomized controlled trials.
10.1371/journal.pone.0035695 · 2012
The effects of Chinese herbal medicines on Madopar dose and adverse reaction during the maintenance phase of Parkinson’s disease: a systematic review with meta-analysis.
2020
Syndrome differentiation and treatment: an essence of traditional Chinese medicine.
2005
Zheng: a systems biology approach to diagnosis and treatments.
2014
Syndrome differentiation in modern research of traditional Chinese medicine.
10.1016/j.jep.2012.01.033 · 2012
Modern bioinformatics meets traditional Chinese medicine.
10.1093/bib/bbt063 · 2014
Overview on pattern identification–history, nature and strategies for treating patients: a narrative review.
10.1016/j.eujim.2020.101101 · 2020
Sequential therapy based on evolvement of patterns: a new model for treatment of Alzheimer’s disease.
10.1007/s11655-019-3066-y · 2019
Traditional Chinese medicine symptom pattern analysis for Parkinson’s disease.
10.1016/s0254-6272(17)30324-2 · 2017
Some crucial problems in establishing chinese medical syndrome differ entiation standards.
2005
Parkinson’s disease subtyping using clinical features and biomarkers: literature review and preliminary study of subtype clustering.
2022
Subtyping early parkinson’s disease by mapping cognitive profiles to brain atrophy with visual MRI ratings.
10.3390/brainsci15070751 · 2025
Microstructural alterations in white matter and related neurobiology based on the new clinical subtypes of Parkinson’s disease.
10.3389/fnins.2024.1439443 · 2024
Identification and prediction of Parkinson’s disease subtypes and progression using machine learning in two cohorts.
10.1038/s41531-022-00439-z · 2022
A multicenter longitudinal study of cholinergic subgroups in Parkinson disease.
10.1038/s41467-025-60815-0 · 2025
Comparison of hierarchical cluster analysis methods by cophenetic correlation.
2013
Distressing dreams and risk of Parkinson’s disease: a population-based cohort study.
10.1016/j.eclinm.2022.101474 · 2022
Isradipine versus placebo in early Parkinson disease: a randomized trial.
10.7326/m19-2534 · 2020
Orthostatic hypotension in Parkinson disease: a 7-year prospective population-based study.
10.1212/wnl.0000000000008314 · 2019
Parkinsonism: onset, progression and mortality.
10.1212/wnl.17.5.427 · 1967
Progression of Parkinson’s disease in the clinical phase: potential markers.
10.1016/s1474-4422(09)70291-1 · 2009
Late-stage parkinson disease.
10.1038/nrneurol.2012.126 · 2012
Levodopa-induced dyskinesia: clinical features, incidence, and risk factors.
10.1007/s00702-018-1900-6 · 2018
Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. The parkinson study Group.
10.1212/wnl.40.10.1529 · 1990
Non-motor symptoms and quality of life in tremor dominant vs postural instability gait disorder Parkinson’s disease patients.
10.1111/ane.12461 · 2016
On bias, variance, 0/1—loss, and the curse-of-dimensionality.
10.1023/a:1009778005914 · 1997
On bias, variance, 0/1—loss, and the curse-of-dimensionality.
10.1023/a:1009778005914 · doi-reference
Non-motor symptoms and quality of life in tremor dominant vs postural instability gait disorder Parkinson’s disease patients.
10.1111/ane.12461 · doi-reference
Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. The parkinson study Group.
10.1212/wnl.40.10.1529 · doi-reference
Levodopa-induced dyskinesia: clinical features, incidence, and risk factors.
10.1007/s00702-018-1900-6 · doi-reference
Late-stage parkinson disease.
10.1038/nrneurol.2012.126 · doi-reference
Progression of Parkinson’s disease in the clinical phase: potential markers.
10.1016/s1474-4422(09)70291-1 · doi-reference
Parkinsonism: onset, progression and mortality.
10.1212/wnl.17.5.427 · doi-reference
Orthostatic hypotension in Parkinson disease: a 7-year prospective population-based study.
10.1212/wnl.0000000000008314 · doi-reference
Isradipine versus placebo in early Parkinson disease: a randomized trial.
10.7326/m19-2534 · doi-reference
Distressing dreams and risk of Parkinson’s disease: a population-based cohort study.
10.1016/j.eclinm.2022.101474 · doi-reference
A multicenter longitudinal study of cholinergic subgroups in Parkinson disease.
10.1038/s41467-025-60815-0 · doi-reference
Identification and prediction of Parkinson’s disease subtypes and progression using machine learning in two cohorts.
10.1038/s41531-022-00439-z · doi-reference
Microstructural alterations in white matter and related neurobiology based on the new clinical subtypes of Parkinson’s disease.
10.3389/fnins.2024.1439443 · doi-reference
Subtyping early parkinson’s disease by mapping cognitive profiles to brain atrophy with visual MRI ratings.
10.3390/brainsci15070751 · doi-reference
Traditional Chinese medicine symptom pattern analysis for Parkinson’s disease.
10.1016/s0254-6272(17)30324-2 · doi-reference
Sequential therapy based on evolvement of patterns: a new model for treatment of Alzheimer’s disease.
10.1007/s11655-019-3066-y · doi-reference
Overview on pattern identification–history, nature and strategies for treating patients: a narrative review.
10.1016/j.eujim.2020.101101 · doi-reference
Modern bioinformatics meets traditional Chinese medicine.
10.1093/bib/bbt063 · doi-reference
Syndrome differentiation in modern research of traditional Chinese medicine.
10.1016/j.jep.2012.01.033 · doi-reference
Herbal medicines for Parkinson’s disease: a systematic review of randomized controlled trials.
10.1371/journal.pone.0035695 · doi-reference
Do Parkinson’s Disease clinical subtypes really exist?
10.5603/pjnns.103572 · doi-reference
Two distinct trajectories of clinical and neurodegeneration events in Parkinson’s disease.
10.1038/s41531-023-00556-3 · doi-reference
Disease progression of data-driven subtypes of Parkinson’s Disease: 5-Year longitudinal study from the early Parkinson’s Disease Longitudinal Singapore (PALS) Cohort.
10.3233/jpd-230209 · doi-reference
Prognosis and neuropathologic correlation of clinical subtypes of Parkinson disease.
10.1001/jamaneurol.2018.4377 · doi-reference
Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression.
10.1093/brain/awx118 · doi-reference
Discovery of Parkinson’s disease states and disease progression modelling: a longitudinal data study using machine learning.
10.1016/s2589-7500(21)00101-1 · doi-reference
Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study.
10.1016/s1474-4422(14)70287-x · doi-reference
Parkinson disease.
10.1038/nrdp.2017.13 · doi-reference
Proteomic analysis of dopamine and α‐synuclein interplay in a cellular model of Parkinson’s disease pathogenesis.
10.1111/j.1742-4658.2010.07896.x · doi-reference